



Expedeon to Present at the Frankfurt Spring Conference

Heidelberg, Germany and Cambridge, UK, 14 May 2019 – Expedeon AG (Frankfurt: EXN; ISIN: DE000A1RFM03; Prime Standard) today announced that CEO Dr Heikki Lanckriet will deliver a presentation on 15 May 2019 at the German Spring Conference in Frankfurt. He will give an update on Company performance, important market trends and key product developments expected over the coming 12 months.

The Expedeon presentation will be held as part of Stream III at 10:00 a.m. and will be available on the Expedeon website from 10:00 am on that day in German and English.

Date: Wednesday, May 15, 2019. 10:00-10:45 a.m. (Stream III)

Venue: Le Méridien Frankfurt, Wiesenhüttenplatz 28-38, 60329 Frankfurt

About the conference: The annual German Spring Conference will be held in Frankfurt am Main from May 13 – 15, 2019. Listed companies will present their latest business figures and their outlook on the upcoming business year to selected investors, analysts, financial journalists and other capital market players. The Spring Conference is a MiFiD II-compliant event for institutional investors and financial analysts, as well as venture capital and private equity investors - participation is free of charge. For more information, please visit <https://equityforum.de/en/german-spring-conference>

For further information, please contact:

Expedeon AG

Dr Heikki Lanckriet

CEO

Phone: +44 1223 873 364

Email: heikki.lanckriet@expedeon.com

Investors' website: <https://investors.expedeon.com/>

MC Services AG (Investor Relations and International Media Relations)

Raimund Gabriel

Managing Partner

Phone: +49 89 210228 0

Email: expedeon@mc-services.eu

About Expedeon AG: www.expedeon.com

Expedeon is an enabler of exciting advances in medical science and patient care. The Company's core technologies, innovative products and services are used in research laboratories around the world,

enabling scientists to push the boundaries of research and product development, and play an integral part in new diagnostic tools being brought to market. With applications spanning the entire workflows in genomics, proteomics and immunology, Expedeon's technologies both accelerate and simplify research and make new and cost-effective processes available to biopharmaceutical and diagnostic organisations alike, thereby underpinning its customers' development and commercialisation objectives. Expedeon's products are sold through a direct sales force and several distribution partners in Europe, the USA and Asia. Expedeon AG has offices in Germany, Spain, UK, USA and Singapore. The Company is listed on the Prime Standard segment of the Frankfurt Stock Exchange (Ticker: EXN; ISIN: DE000A1RFM03).

This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of Expedeon AG may deviate greatly from the established conclusions or implied predictions contained in such statements. Expedeon does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. # #